MedTrace Logo

Enfortumab Vedotin-Ejfv

Drug

Drug Profile

Enfortumab vedotin is an antibody-drug conjugate anti-cancer therapy marketed as Padcev for advanced urothelial cancer settings. It is a nectin-4-directed antibody linked to a microtubule inhibitor payload (MMAE). The FDA first approved it in 2019.

Drug Class
Nectin-4-directed antibody-drug conjugate; microtubule inhibitor conjugate
Approval Status
FDA approved in December 2019, with additional U.S. approval updates in 2021; EU approval in April 2022
Mechanism of Action
Targets nectin-4 via monoclonal antibody and delivers vedotin (MMAE) microtubule-inhibitor payload
Brand Names
  • Padcev
Indications
  • \Locally advanced or metastatic urothelial cancer after prior PD-1/PD-L1 inhibitor and platinum-containing chemotherapy, including specified cisplatin-ineligible settings\

Related News

FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth

The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.

Related Clinical Trials

NCT ID Title Status Phase
NCT04887870

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

 COMPLETED PHASE2/PHASE3